PACIRA BIOSCIENCES INC (PCRX) Stock Fundamental Analysis
NASDAQ:PCRX • US6951271005
23.11 USD
-0.11 (-0.47%)
At close: Feb 23, 2026
23.11 USD
0 (0%)
After Hours: 2/23/2026, 4:20:00 PM
Overall PCRX gets a fundamental rating of 6 out of 10. We evaluated PCRX against 192 industry peers in the Pharmaceuticals industry. While PCRX has a great profitability rating, there are some minor concerns on its financial health. PCRX is cheap, but on the other hand it scores bad on growth. With these ratings, PCRX could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
- In the past year PCRX was profitable.
- PCRX had a positive operating cash flow in the past year.
- Of the past 5 years PCRX 4 years were profitable.
- Each year in the past 5 years PCRX had a positive operating cash flow.
1.2 Ratios
- With an excellent Return On Assets value of 1.65%, PCRX belongs to the best of the industry, outperforming 81.25% of the companies in the same industry.
- PCRX has a better Return On Equity (2.95%) than 82.29% of its industry peers.
- PCRX's Return On Invested Capital of 3.63% is amongst the best of the industry. PCRX outperforms 82.29% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for PCRX is significantly below the industry average of 12.95%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.65% | ||
| ROE | 2.95% | ||
| ROIC | 3.63% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.3%
ROIC(5y)4.55%
1.3 Margins
- PCRX has a better Profit Margin (2.99%) than 80.73% of its industry peers.
- The Operating Margin of PCRX (8.88%) is better than 81.25% of its industry peers.
- PCRX's Operating Margin has improved in the last couple of years.
- With an excellent Gross Margin value of 79.17%, PCRX belongs to the best of the industry, outperforming 84.90% of the companies in the same industry.
- PCRX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.88% | ||
| PM (TTM) | 2.99% | ||
| GM | 79.17% |
OM growth 3Y-15.96%
OM growth 5Y11.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PCRX is destroying value.
- The number of shares outstanding for PCRX has been reduced compared to 1 year ago.
- The number of shares outstanding for PCRX has been increased compared to 5 years ago.
- PCRX has a worse debt/assets ratio than last year.
2.2 Solvency
- PCRX has an Altman-Z score of 1.92. This is not the best score and indicates that PCRX is in the grey zone with still only limited risk for bankruptcy at the moment.
- PCRX has a better Altman-Z score (1.92) than 62.50% of its industry peers.
- PCRX has a debt to FCF ratio of 3.03. This is a good value and a sign of high solvency as PCRX would need 3.03 years to pay back of all of its debts.
- Looking at the Debt to FCF ratio, with a value of 3.03, PCRX belongs to the top of the industry, outperforming 91.67% of the companies in the same industry.
- A Debt/Equity ratio of 0.52 indicates that PCRX is somewhat dependend on debt financing.
- PCRX's Debt to Equity ratio of 0.52 is on the low side compared to the rest of the industry. PCRX is outperformed by 61.98% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 3.03 | ||
| Altman-Z | 1.92 |
ROIC/WACC0.46
WACC7.86%
2.3 Liquidity
- A Current Ratio of 5.26 indicates that PCRX has no problem at all paying its short term obligations.
- Looking at the Current ratio, with a value of 5.26, PCRX is in the better half of the industry, outperforming 65.10% of the companies in the same industry.
- A Quick Ratio of 3.78 indicates that PCRX has no problem at all paying its short term obligations.
- PCRX has a Quick ratio (3.78) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.26 | ||
| Quick Ratio | 3.78 |
3. Growth
3.1 Past
- The earnings per share for PCRX have decreased by -6.90% in the last year.
- PCRX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.96% yearly.
- PCRX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -16.85%.
- The Revenue has been growing by 10.73% on average over the past years. This is quite good.
EPS 1Y (TTM)-6.9%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-11.39%
Revenue 1Y (TTM)-16.85%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%6.49%
3.2 Future
- The Earnings Per Share is expected to grow by 7.01% on average over the next years.
- Based on estimates for the next years, PCRX will show a small growth in Revenue. The Revenue will grow by 6.79% on average per year.
EPS Next Y-6.13%
EPS Next 2Y4.05%
EPS Next 3Y6.92%
EPS Next 5Y7.01%
Revenue Next Year4.33%
Revenue Next 2Y6.28%
Revenue Next 3Y7.3%
Revenue Next 5Y6.79%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- PCRX is valuated cheaply with a Price/Earnings ratio of 7.78.
- 94.27% of the companies in the same industry are more expensive than PCRX, based on the Price/Earnings ratio.
- When comparing the Price/Earnings ratio of PCRX to the average of the S&P500 Index (26.99), we can say PCRX is valued rather cheaply.
- A Price/Forward Earnings ratio of 6.65 indicates a rather cheap valuation of PCRX.
- Based on the Price/Forward Earnings ratio, PCRX is valued cheaply inside the industry as 93.75% of the companies are valued more expensively.
- The average S&P500 Price/Forward Earnings ratio is at 28.02. PCRX is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.78 | ||
| Fwd PE | 6.65 |
4.2 Price Multiples
- 95.31% of the companies in the same industry are more expensive than PCRX, based on the Enterprise Value to EBITDA ratio.
- Based on the Price/Free Cash Flow ratio, PCRX is valued cheaper than 94.27% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.65 | ||
| EV/EBITDA | 6.38 |
4.3 Compensation for Growth
- PCRX has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.56
EPS Next 2Y4.05%
EPS Next 3Y6.92%
5. Dividend
5.1 Amount
- PCRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
23.11
-0.11 (-0.47%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)02-26 2026-02-26/amc
Inst Owners114.44%
Inst Owner Change-2.99%
Ins Owners0.79%
Ins Owner Change16.54%
Market Cap949.82M
Revenue(TTM)716.79M
Net Income(TTM)21.44M
Analysts76.92
Price Target30.31 (31.16%)
Short Float %19.55%
Short Ratio8.74
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.71%
Min EPS beat(2)2.13%
Max EPS beat(2)5.28%
EPS beat(4)4
Avg EPS beat(4)4.05%
Min EPS beat(4)1.99%
Max EPS beat(4)6.81%
EPS beat(8)6
Avg EPS beat(8)5.89%
EPS beat(12)7
Avg EPS beat(12)1.4%
EPS beat(16)8
Avg EPS beat(16)-3.85%
Revenue beat(2)0
Avg Revenue beat(2)-3.29%
Min Revenue beat(2)-3.59%
Max Revenue beat(2)-2.99%
Revenue beat(4)0
Avg Revenue beat(4)-3.23%
Min Revenue beat(4)-5.92%
Max Revenue beat(4)-0.42%
Revenue beat(8)1
Avg Revenue beat(8)-2.14%
Revenue beat(12)1
Avg Revenue beat(12)-2.68%
Revenue beat(16)1
Avg Revenue beat(16)-2.53%
PT rev (1m)0%
PT rev (3m)-19.69%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.75%
EPS NY rev (1m)0%
EPS NY rev (3m)2.87%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.11%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.99%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.78 | ||
| Fwd PE | 6.65 | ||
| P/S | 1.33 | ||
| P/FCF | 7.65 | ||
| P/OCF | 6.72 | ||
| P/B | 1.31 | ||
| P/tB | 2.93 | ||
| EV/EBITDA | 6.38 |
EPS(TTM)2.97
EY12.85%
EPS(NY)3.48
Fwd EY15.04%
FCF(TTM)3.02
FCFY13.08%
OCF(TTM)3.44
OCFY14.89%
SpS17.44
BVpS17.69
TBVpS7.9
PEG (NY)N/A
PEG (5Y)0.56
Graham Number34.39
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.65% | ||
| ROE | 2.95% | ||
| ROCE | 5.34% | ||
| ROIC | 3.63% | ||
| ROICexc | 4.58% | ||
| ROICexgc | 7.99% | ||
| OM | 8.88% | ||
| PM (TTM) | 2.99% | ||
| GM | 79.17% | ||
| FCFM | 17.33% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.3%
ROIC(5y)4.55%
ROICexc(3y)6.05%
ROICexc(5y)7.29%
ROICexgc(3y)13.64%
ROICexgc(5y)24.93%
ROCE(3y)6.32%
ROCE(5y)6.69%
ROICexgc growth 3Y-33.29%
ROICexgc growth 5Y14.33%
ROICexc growth 3Y-3.13%
ROICexc growth 5Y10.2%
OM growth 3Y-15.96%
OM growth 5Y11.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
F-Score7
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 3.03 | ||
| Debt/EBITDA | 2.44 | ||
| Cap/Depr | 18.95% | ||
| Cap/Sales | 2.4% | ||
| Interest Coverage | 4.07 | ||
| Cash Conversion | 91.52% | ||
| Profit Quality | 579.36% | ||
| Current Ratio | 5.26 | ||
| Quick Ratio | 3.78 | ||
| Altman-Z | 1.92 |
F-Score7
WACC7.86%
ROIC/WACC0.46
Cap/Depr(3y)22.15%
Cap/Depr(5y)83.49%
Cap/Sales(3y)2.76%
Cap/Sales(5y)5.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.9%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-11.39%
EPS Next Y-6.13%
EPS Next 2Y4.05%
EPS Next 3Y6.92%
EPS Next 5Y7.01%
Revenue 1Y (TTM)-16.85%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%6.49%
Revenue Next Year4.33%
Revenue Next 2Y6.28%
Revenue Next 3Y7.3%
Revenue Next 5Y6.79%
EBIT growth 1Y-45.68%
EBIT growth 3Y-8.41%
EBIT growth 5Y23.37%
EBIT Next Year1.3%
EBIT Next 3Y6.32%
EBIT Next 5Y6.85%
FCF growth 1Y-4.68%
FCF growth 3Y30.84%
FCF growth 5Y24.28%
OCF growth 1Y-5.2%
OCF growth 3Y14.64%
OCF growth 5Y21.85%
PACIRA BIOSCIENCES INC / PCRX FAQ
What is the ChartMill fundamental rating of PACIRA BIOSCIENCES INC (PCRX) stock?
ChartMill assigns a fundamental rating of 6 / 10 to PCRX.
What is the valuation status for PCRX stock?
ChartMill assigns a valuation rating of 8 / 10 to PACIRA BIOSCIENCES INC (PCRX). This can be considered as Undervalued.
How profitable is PACIRA BIOSCIENCES INC (PCRX) stock?
PACIRA BIOSCIENCES INC (PCRX) has a profitability rating of 7 / 10.
What is the valuation of PACIRA BIOSCIENCES INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for PACIRA BIOSCIENCES INC (PCRX) is 7.78 and the Price/Book (PB) ratio is 1.31.